What Late-Breakers To Look Out For At ASCO 2019

 
• By Alexandra Shimmings

Delegates at this year’s ASCO meeting in Chicago will hear late-breaking clinical data for a number of studies from AstraZeneca, Novartis, Pfizer, Astellas, Merck & Co and Seattle Genetics which are set to shake up their respective markets. There will also be more clarity on where Lilly’s Lartruvo went so wrong.

Stage
Setting the Stage for ASCO 2019 • Source: Shutterstock

More from ASCO

More from Conferences